echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > What does it mean to go from "recruitment" to "price acquisition"?

    What does it mean to go from "recruitment" to "price acquisition"?

    • Last Update: 2022-06-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    From the "Recruitment Center" to the "Price Purchase Center", the difference in the name is like a butterfly flapping its wings.
    Industry insiders predict that this change may indicate that the era of in-depth price linkage between "three doctors" is coming.
    on

    .

    After the normalization of centralized procurement, the provincial bidding and procurement platforms for drugs and medical consumables will also usher in functional upgrades
    .

    Since the National Medical Insurance Bureau started the national centralized procurement in 2018, all provinces have established provincial-level bidding and procurement platforms for drugs and medical consumables
    .

    At present, the provincial centralized procurement institutions are mainly divided into three types according to their functional jurisdiction:

    Public institutions directly under the management of the provincial medical security bureau, and the pharmaceutical procurement platform is independently constructed by the centralized procurement agency.
    Such cases include a total of 15 provinces such as Beijing, Tianjin, and Shanghai;

    The Provincial Medical Security Bureau and the provincial public resource transaction service management department jointly established a centralized procurement agency, and unified the procurement platform in the provincial public resource transaction service platform.
    Such cases include Shandong, Hubei, Shaanxi and other 16 provinces;

    Provincial state-owned enterprises are responsible for the centralized procurement of medicines in medical institutions across the province, including the Guangdong Provincial Drug Exchange and the Chongqing Drug Exchange
    .

    A few days ago, the National Medical Insurance Bureau held the first working meeting of national pharmaceutical centralized procurement institutions to study and deploy the construction of the centralized procurement platform
    .

    At the meeting, Chen Jinfu, member of the party group and deputy director of the Medical Insurance Bureau, emphasized that it is necessary to fully understand the importance of platform construction to support the reform of centralized pharmaceutical procurement, explore new price formation mechanisms and professional handling services, and focus on supporting the reform and management of pharmaceutical prices.
    The overall goal of the company is to continue to improve and improve the functions of transaction support, online settlement, monitoring and supervision, and public services, focusing on improving the rate of online collection and centralized collection, standardizing the rules of hanging online, promoting online settlement, strengthening monitoring and supervision, and participating in medical treatment.
    The reform of service prices, the improvement of information systems and the creation of demonstration platforms,

    etc.

    01.
    What does the "Price Acquisition Center" do?

    01.
    What does the "Price Acquisition Center" do?

    As we all know, the main functions of the centralized procurement platforms in various provinces are centralized procurement, data management, decision support, supervision assistance, business consulting, information tracking, complaint investigation and scientific research
    .
    However, the functional performance of participating in the price reform of medical services and exploring new price formation mechanisms and management has not been clearly highlighted

    .
    Jiangxi has explored this aspect

    .
    According to China Medical Insurance, the only media platform of the National Medical Insurance Bureau, in the report of the National Pharmaceutical Centralized Purchasing Agency Work Conference, the work of the Jiangxi Provincial Centralized Purchasing Agency was specially mentioned: Jiangxi Provincial Medicine Price and Purchasing Service Center actively innovated, Increase institutional functions, make up for the shortcomings of medical service price project management, and realize the transformation and remodeling from "recruitment center" to "price procurement center"

    .
    From the change of name alone, it means that the function of the recruitment and procurement center has expanded and upgraded.
    An expert close to the Medical Insurance Bureau said in an interview with the E-pharmaceutical manager that the traditional "recruitment and procurement center" generally only involves drugs and consumables.
    Or the online and transaction of Chinese herbal decoction pieces, etc.
    , to the "price procurement center", which may mean that its business scope has expanded to technical support such as medical price management, and may also involve the price of medical services

    .
    The centralized pharmaceutical procurement platform is the basic support for the centralized procurement of drugs and medical consumables, and the promotion of pharmaceutical price reform and management

    .
    In January 2022, the National Medical Insurance Bureau mentioned that it will further improve the platform functions, promote the formation of a medical supply guarantee system, and improve the modernization level of medical price governance

    .
    It is also clarified that the centralized pharmaceutical procurement platform should expand the coverage and expand the main body of procurement to cover all public medical institutions

    .
    Strengthen the monitoring of medical prices and expand the scope and content of monitoring

    .
    Establish a collaborative linkage mechanism, improve the level of data connectivity and sharing between platforms, such as price, credit evaluation, and supply, and promote the formation of a unified and open centralized procurement market across the country

    .
    At the same time, this also indicates that the functions of the provincial recruitment platform are further aligned with the functions of relevant national institutions.

    .
    The official website of the National Medical Insurance Administration shows that the main functions of the Department of Medicine Price and Bidding and Purchasing show that the agency's responsibilities are: to formulate policies such as the prices of drugs, medical consumables, medical service items, and charges for medical service facilities, and to organize and implement them.
    release system

    .
    Formulate and supervise the implementation of bidding procurement, distribution and settlement management policies for drugs and medical consumables, and promote the construction of bidding and procurement platforms

    .
    Industry insiders predict that this change may indicate that the era of in-depth linkage of "three doctors" is about to begin, especially in the form and mechanism of drug prices and price transmission, the depth and frequency of mutual influence will increase

    .
    In 2021, the National Medical Insurance Bureau and eight departments jointly issued the "Deepening Medical Service Price Reform Pilot Plan" to answer a reporter's question.
    The relevant person in charge of the Medical Insurance Bureau explained that the price reduction and fee reduction for centralized purchases will not be "finished" through the adjustment of medical service prices.
    In a disguised form, the translation, conversion and transfer of medical expenses can be realized

    .
    Instead, centralized procurement has created a favorable opportunity for the reform of medical service prices and won a window for the reform of medical service prices

    .
    It is further clarified that the two reforms each have their own internal logic.
    The purpose of centralized procurement is to "sell with gold" for pharmaceutical consumables, with the purpose of purifying the market environment, squeezing out the price water, and reducing the unreasonable burden of the people; the medical service price reform is aimed at The purpose of its own shortcomings is to build a more scientific and reasonable price mechanism and better leverage its leverage

    .
    "Sensitivity and sensitivity" is the requirement for the dynamic price adjustment mechanism proposed in the "Pilot Plan for Deepening the Reform of Medical Service Prices"

    .
    In fact, such a case was shown in the "Notice of the Party Group of the National Medical Security Administration of the Communist Party of China on the Sixth Round of Inspection, Rectification and Improvement of the Nineteenth Central Committee"

    .
    According to the "Notice": in cooperation with the centralized procurement of coronary stents, guide the provinces with a large proportion of non-local patients and the current price is lower than the national median price to adjust the price of coronary surgery.
    To about 8,300 yuan; cooperate with the second batch of the state to organize the centralized procurement of high-value medical consumables (artificial joints), and study the technical guidelines for the price adjustment of "artificial joint replacement" surgery

    .
    However, after adjusting the price of medical services to the current plan, what impact will it have on pharmaceutical companies, especially the price of drug procurement? E-pharmaceutical managers learned two diametrically opposed views in interviews

    .
    One point of view is that the impact on pharmaceutical companies will be positive and positive

    .
    After the price of medical services is adjusted according to actual needs and different economic conditions in various places, the value of medical technical services for doctors is highlighted, and the income of sunshine has increased, thereby reducing the previous situation that enterprises need to compensate for the loss of medical services through various means, and enterprises can focus on innovation.
    , improve product quality

    .
    Another point of view is that in the long run, if the centralized procurement platform monitors the dynamic balance between the winning price of pharmaceutical equipment, the use of medical institutions and the price of medical services, then the pharmaceutical companies will face huge challenges in maintaining prices in the market

    .
    In order to ensure the sustainability of medical insurance funds, if the supply chain factors such as raw material price increases are not considered, prices may fall into a spiral of continuous decline

    .
    It is reported that in accordance with the deployment of the "Deepening the Pilot Program for the Reform of Medical Service Prices", 5 cities have been selected in the country for 3 to 5 years of pilot projects to explore the formation of replicable and scalable medical service price reform experience, and then gradually promote it nationwide

    .
    Ganzhou, Jiangxi Province, was selected as one of the national pilot cities, and will be directly contacted and guided by the National Medical Security Administration, focusing on pilot projects focusing on mechanisms such as total volume regulation, price classification formation and dynamic adjustment, and monitoring and assessment

    .

    02.
    "Jiangxi Model" of centralized procurement

    02.
    "Jiangxi Model" of centralized procurement

    Linking between volume and price, direct settlement, and the percentage of surplus retained and rewarded to medical institutions are the main practices in the implementation of centralized procurement of pharmaceutical and medical consumables in Jiangxi Province
    .
    At the press conference on the effectiveness of centralized procurement of medicines and medical consumables in Jiangxi Province in 2021 held by the province, Liang Yimin, a first-level inspector of the Jiangxi Provincial Medical Security Bureau, said that he insisted on linking volume and price, ensuring use, integrating recruitment and procurement, and directly Settlement is the basic principle of doing a good job in the centralized procurement of medicines and medical consumables

    .
    In terms of linking volume and price, Jiangxi Province has changed the original purchase and sales model of medicines and medical consumables, reduced corporate public relations and sales expenses, and made the medicines and medical supplies scattered by public medical institutions.
    The procurement of medical consumables is concentrated to form a large-scale group purchase effect.
    Enterprises make independent quotations according to the procurement volume, and give full play to the internal mechanism of market discovery of prices

    .
    For the sales payment that enterprises are most concerned about, Jiangxi Province has realized the implementation of medical insurance funds and The
    supplier company directly settles the payment, becoming one of the first three provinces in the country

    .
    The figures disclosed by Liang Yimin at the above meeting show that the settlement rate of the next month's payment for the centralized procurement of medicines in Jiangxi Province is close to 100%

    .
    In terms of specific incentives and risk sharing mechanisms , Jiangxi Province stipulates the principle of "total management, balance retention, reasonable overspending", and encourages public medical institutions to use selected drugs

    .
    The medical insurance surplus funds generated by purchasing with volume will be rewarded according to the proportion of 30%-50% after passing the assessment.
    Public medical institutions; part of the remaining balance is used to dynamically adjust the prices of medical service items, mainly to prioritize the adjustment of the prices of medical service items that reflect the value of medical personnel’s technical labor services, and to gradually straighten out the price parity relationship between medical service items

    .
    Jiangxi Province is constantly striving to upgrade the "Jiangxi Model"

    of centralized procurement.
    For example, Jiangxi provincial centralized procurement is mainly carried out for unreviewed drugs, and has optimized the "two-envelope" system, integrating economic and technical standards and business standards according to 6:4 "Two passes and three eliminations" are implemented

    .
    That is, bidders whose economic and technical bid scores are lower than 70 points will be directly eliminated, those who are not shortlisted for commercial bids will be directly eliminated in proportion, and those whose comprehensive evaluation score is lower than 75 points will be directly eliminated after two passes.

    .
    Due to the lack of "gold standards" for unreviewed drugs, Jiangxi took the lead in introducing drug quality inspection indicators to check the quality of unreviewed drugs, highlighting quality and safety standards, and scoring according to the actual inspection value of drugs, which was fully affirmed by the National Medical Security Administration

    .
    In terms of variety selection, Jiangxi Province selects drugs with a large amount and a high purchase price and sufficient competition.
    In the selection rules, not only the low price is selected, but the product of the enterprise with the lowest quotation and the enterprise with the highest comprehensive evaluation score shall be selected.
    selected

    .
    Taking into account the quality and price of drugs, the lowest price and highest score enterprises after the comprehensive review are selected, and all review rules and review results are made public

    .
    In terms of scoring rules, Jiangxi is also more refined.
    For example, in the economic and technical scoring rules for the drug procurement of the four provinces of Gansu, Guangdong, Henan and Hubei, the patented drugs, visible foreign bodies, insoluble particles, quality system, and delivery rate within five days will be obtained.
    , unresponsive order rate, delivery method, etc.
    are all included in the assessment

    .
    The data shows that in 2020, Jiangxi Province completed the first batch of unreviewed drug purchases with volume, and 6 drugs were selected, with an average drop of 60% and a maximum drop of 96%, which is comparable to the drop in the centralized drug procurement organized by the state, saving money every year.
    Over 100 million yuan

    .
    In 2021, Jiangxi Province will further enlarge the "coordinate system", lead the formation of a cross-provincial centralized procurement alliance for the first time, and form a four-provincial alliance with Guangdong, Henan, and Hubei to carry out the second batch of unreviewed drug centralized procurement

    .
    Calculated according to the agreed procurement volume in the first year of the alliance, it is estimated that the annual savings will be 167 million yuan

    .
    At the same time, Jiangxi Province also copied the experience and practice of centralized drug procurement to the field of medical consumables

    .
    In the first batch of coronary guide catheters and coronary guide wire centralized collection, Jiangxi Province took the lead in forming a nine-province alliance including Hebei, Shandong, Henan, Hubei, Guangxi, Chongqing, Yunnan, and Shaanxi.
    The alliance intends to The purchase volume is close to half of the national market share

    .
    According to the Jiangxi Provincial Medical Insurance Bureau, since the implementation of the first batch of nationally organized drug centralized procurement results on December 20, 2019, Jiangxi Province has successively landed 13 batches of drug and medical consumables centralized procurement results, covering 224 drugs, 3 categories High-value medical consumables, Type 2 testing reagents, Type 1 low-value medical consumables, etc.
    Among them, the average drop of medicines is 62%, the highest drop is 98%, the average drop of medical consumables is 77%, the highest drop is 94%, and the annual savings exceeds 50% billion

    .
     

    References:

    References:

    China Medical Insurance "The First Work Conference of National Pharmaceutical Collective Institutions, Released This Information"

    China Medical Insurance "The First Work Conference of National Pharmaceutical Collective Institutions, Released This Information"

    People's Daily Online "Medical Service Price Welcomes Major Reform Interpretation of the National Medical Insurance Bureau: Price Reform is not a Simple Price Adjustment"

    People's Daily Online "Medical Service Price Welcomes Major Reform Interpretation of the National Medical Insurance Bureau: Price Reform is not a Simple Price Adjustment"

    National Medical Insurance Administration "National Medical Security Administration Deploys and Improves the Functions of the Centralized Medicine Purchasing Platform"

    National Medical Insurance Administration "National Medical Security Administration Deploys and Improves the Functions of the Centralized Medicine Purchasing Platform"
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.